Coherus provides preliminary Q4/FY2024 revenue and cash; UDENYCA allocated due to strong demand

Coherus Oncology, Inc.

2024-FY EPS reported $0.25 revenue$266,960,000

Preliminary unaudited net revenues for Q4 and FY2024 presented at J.P. Morgan Healthcare Conference.
Cash, cash equivalents and investments as of Dec 31, 2024 disclosed; final results may materially differ.
All three presentations of UDENYCA temporarily allocated due to strong demand in Q4 2024 and into Q1 2025.
Financial closing procedures not yet complete; independent auditor has not reviewed these preliminary results.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.